2 completed, 1 withdrawn. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Withdrawn 1 |
Follow GlucaGen: new trials by email Literature Review of GlucaGen trials Research Report on GlucaGen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Stable Glucagon Analog Administered by a Bihormonal Closed Loop System Dasiglucagon, GlucaGen - Diabetes Mellitus, Type 1 | Phase 2 | Withdrawn | Inreda Diabetic B.V. | 2023-12-29 | 2024-01-03 | |
| Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon ZP4207, GlucaGen - Hypoglycemia | Phase 2 | Completed | Zealand Pharma | 81 | 2016-01-01 | 2016-06-15 |
| Sensor-Augmented Insulin Delivery: Insulin Plus Glucagon Versus Insulin Alone Insulin, Asp(B28)-, Glucagon, Placebo - Type 1 Diabetes | Phase 2 | Completed | Legacy Health System | 14 | 2008-11-01 | 2011-10-07 |
Diabetes Mellitus, Type 1 (2) · Hypoglycemia (2) · Diabetes Mellitus (1) · Insulin Resistance (1)
Inreda Diabetic B.V. (1) · Legacy Health System (1) · Zealand Pharma (1)
Germany (1) · Netherlands (1) · United States (1)
G Laverman, MD (1) · William K. Ward, MD (1)